“CemiplimAb-rwlc Survivorship and Epidemiology (CASE): A prospective study of the safety and efficacy of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC) in a real-world setting” (2023) SKIN The Journal of Cutaneous Medicine, 7(2), p. s174. doi:10.25251/skin.7.supp.174.